New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:03 EDTOXFDOxford Immunotec growth looks robust, says RW Baird
Baird believes the growth outlook for Oxford Immunotec remains robust and they believe the company is in the early stages of penetrating the large global market for latent TB testing. Shares are Outperform rated and price target raised to $27 from $21.
News For OXFD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:11 EDTOXFDOxford Immunotec sees FY15 revenue $60M-$65M, consensus $64.31M
Subscribe for More Information
07:11 EDTOXFDOxford Immunotec sees Q1 revenue $13.2M-$13.7M, consensus $14.53M
Subscribe for More Information
07:10 EDTOXFDOxford Immunotec reports Q4 EPS (39c), consensus (44c)
Reports Q4 revenue $12.1M, consensus $11.93M.
February 27, 2015
20:51 EDTOXFDOxford Immunotec management to meet with Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use